PSYCH Symposium: London

PSYCH: The Psychedelics Symposiumbrings  together key stakeholders at the forefront  of the psychedelics space to share unparalleled  insights and intelligence. Leaders from the  worlds of healthcare, science and business will  present their latest findings and expert analysis  on the state of the industry in unique locations  across the globe.

PSYCH

PSYCH Symposium: London will be hosted at the iconic National Gallery on Wednesday, 11 May 2022.

The National Gallery

<h2>Hosted at the prestigious National Gallery, <a href="https://www.psychsymposium.com/" target="_blank" data-msys-clicktrack="0" rel="nofollow noopener noreferrer">PSYCH Symposium: London</a> provides a platform for the industry’s most influential figures to connect and collaborate. </h2><p>As our collective understanding of psychedelic medicines shift dramatically, we are witnessing a global rise in clinical trials, academic research and commercial investment. </p><p>Spanning the entire emerging ecosystem, the  programme will feature research updates and company presentations from organisations at the forefront of psychedelic research. </p><p>This exclusive conference will provide the insights that unlock the global potential of psychedelics as medicine, alongside best-in-class networking experiences.</p><h3><a href="https://www.psychsymposium.com/speakers" target="_blank" data-msys-clicktrack="0" rel="nofollow noopener noreferrer">Speakers</a>, <a href="https://www.psychsymposium.com/sponsorship" target="_blank" data-msys-clicktrack="0" rel="nofollow noopener noreferrer">Sponsors</a> and companies of note attending include:</h3><ul><li>Beckley Foundation, based in Oxford, which has been studying psychedelic medicines for the past thirty years</li><li>COMPASS Pathways, based in Altrincham, is NASDAQ listed with a market cap of US$565m</li><li>Professor David Nutt, Professor of Neuropsychopharmacology at Imperial College London and Chair of UK policy think tank Drug Science</li><li>Member of Parliament Crispin Blunt, who has championed the campaign to reschedule psychedelic medicines in Westminster</li><li>Rick Doblin, founder of US non-profit multidisciplinary association for psychedelic studies (“MAPS”), which has raised over ​​US$130 million for research into the field</li></ul><p>Secure your ticket and navigate the emerging landscapes of psychedelic healthcare, with the market intelligence to stay ahead of the curve.</p><h3>Tickets include:</h3><ul><li>Entry to the PSYCH Symposium at The National Gallery, London on 11 May. </li><li>Entry to the post-summit rooftop terrace drinks reception, overlooking Trafalgar Square.</li><li>Best-in-class discussions and debates with influential figures shaping meaningful change in the space - including live Q&amp;A opportunities. </li><li>Exclusive networking opportunities with speakers and sponsors.</li><li>Access to the event networking app, featuring the full attendee list with meeting scheduling functionality - making it easy to collaborate. </li><li>Use of meeting rooms, networking spaces and on-site cloakroom.</li></ul>

Our {communityGuidelinesLink} describe the sort of content we prohibit on Eventbrite. If you suspect an event may be in violation, you can report it to us so we can investigate.

To report other categories of prohibited or illegal content, submit {link}

PSYCH Symposium: London

More events from PSYCH

Discover more events from PSYCH, from Business to other experiences you might love.

PSYCH Symposium: London

More events from PSYCH

Discover more events from PSYCH, from Business to other experiences you might love.

You might also like...

Browse more events with different dates, prices, and formats to find your next great experience.